Rahika 150mg Tablet

Tablet
Rs.13593.75for 1 strip(s) (12 tablets each)
1
Unfortunately, we don't have any more items in stock
Report Error

Composition FOR Rahika 150mg Tablet

Capmatinib(150mg)

food interaction for Rahika Tablet

alcohol interaction for Rahika Tablet

pregnancy interaction for Rahika Tablet

lactation interaction for Rahika Tablet

food
alcohol
pregnancy
lactation
Rahika 150mg Tablet may be taken with or without food.
None
CAUTION
It is not known whether it is safe to consume alcohol with Rahika 150mg Tablet. Please consult your doctor.
CONSULT YOUR DOCTOR
Rahika 150mg Tablet is not recommended during pregnancy as there is positive evidence of fetal risk based on animal studies. However, it may still be prescribed by a doctor in situations where the benefits outweigh the risks.
CONSULT YOUR DOCTOR
Rahika 150mg Tablet is unsafe to use during breastfeeding. Data suggests that the drug may cause toxicity to the baby.
UNSAFE

SALT INFORMATION FOR Rahika 150mg Tablet

Capmatinib(150mg)

Rahika tablet uses

{med_name} is used in the treatment of non-small cell lung cancer.

How rahika tablet works

Rahika 150mg Tablet works by blocking the activity of a protein called MET, including its abnormal form caused by a genetic alteration known as MET exon 14 skipping. This blocks signals that promote the growth and survival of cancer cells, helping slow or stop their growth.

Common side effects of rahika tablet

Edema (swelling), Nausea, Musculoskeletal (bone, muscle or joint) pain, Fatigue, Vomiting, Breathlessness, Cough, Decreased appetite

SUBSTITUTES FOR Rahika Tablet

No substitutes found

Expert advice FOR Rahika Tablet

  • Take Capmatinib exactly as prescribed by your doctor. Swallow it whole without crushing, breaking, or chewing. Do not change your dose or stop treatment without consulting your doctor.
  • Your doctor will perform blood tests before and during treatment to monitor your liver and pancreatic function. Do not miss any scheduled tests or follow-up appointments.
  • Inform your doctor immediately if you develop a new or worsening cough, fever, difficulty breathing, or shortness of breath, as these may indicate serious lung problems.
  • Contact your doctor if you notice yellowing of the skin or eyes, dark urine, severe stomach pain, or persistent nausea and vomiting, as these may indicate liver or pancreatic problems.
  • Capmatinib may make your skin more sensitive to sunlight. Limit direct sun exposure and use sunscreen or wear protective clothing when outdoors.
  • Inform your doctor about all medicines you are taking, including vitamins, and herbal supplements, as some may interact with Capmatinib.
  • Use effective contraception during treatment and for 1 week after the last dose. Avoid breastfeeding during treatment and for 1 week after the last dose.

Frequently asked questions FOR Rahika 150mg Tablet

Capmatinib

Q. What is Rahika 150mg Tablet and what is it used for?
Rahika 150mg Tablet is a prescription medicine used to treat adults with a kind of lung cancer called non-small cell lung cancer (NSCLC) that has spread to other parts of the body or cannot be removed by surgery and whose tumors have an abnormal gene.
Q. Can Rahika 150mg Tablet be taken during pregnancy?
This treatment may harm a baby developing in the womb. It is important not to conceive during and for 1 week after your last dose of Rahika 150mg Tablet. Talk to your doctor about effective contraception before starting the treatment.
Q. How many times a day can I take Rahika 150mg Tablet?
This medicine is to be taken twice a day with or without food or as advised by your doctor. It is advisable not to change your dose or stop taking this medicine unless the doctor tells you to.
Show More
Q. What tests will be prescribed before starting the treatment with Rahika 150mg Tablet?
You will be prescribed a liver test to assess how well your liver is working before and during the treatment. Inform your doctor immediately if you develop any signs and symptoms of liver problems, including your skin or the white part of your eyes turning yellow, nausea, vomiting, loss of appetite, dark-colored urine, or stomach pain.
Q. Is Rahika 150mg Tablet a targeted therapy?
Yes, Rahika 150mg Tablet is the first targeted therapy designed specifically for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping.
Q. Which is better, targeted therapy or chemotherapy?
Both chemotherapy and targeted therapy are two effective methods for cancer therapy. The difference is that chemotherapy can also kill normal cells when destroying cancer cells. On the other hand, targeted therapy does not affect normal cells while killing the targeted cancer cells.
Q. What should I avoid while taking Rahika 150mg Tablet?
Your skin may become sensitive to the sun (photosensitivity) during treatment with this medicine. Use a sunscreen or wear clothes that cover your skin during your treatment to limit direct sunlight exposure.
Q. I am experiencing nausea and extreme tiredness. Is this due to Rahika 150mg Tablet?
Nausea and fatigue or tiredness are some of the common side effects of this medicine. Eat smaller, more frequent meals to reduce the feeling of nausea. Avoid food that is salty, spicy, fried, or fatty. Get plenty of rest and do light exercise daily to keep yourself active and reduce fatigue.
Q. Should I avoid any food and drinks while taking Rahika 150mg Tablet?
You can continue with your normal diet unless your doctor tells you otherwise. However, it is advisable to sip water regularly to prevent dehydration, eat small, simple but nourishing snacks every few hours rather than large meals, and suck on hard candy or popsicles to prevent nausea and vomiting.
Q. I am noticing swelling in the lower legs and ankles. Should I inform my doctor?
You might experience swelling in different parts of your body while taking Rahika 150mg Tablet. Inform your doctor, as they may change your dose, temporarily stop, or permanently stop the treatment according to the side effects.

Content on this page was last updated on 12 November, 2026, by Dr. Sachin Gupta (MD Pharmacology, MBBS)